NCT07331558 Multimodal VR Rehabilitation for Cardiorespiratory Fitness in CABG Phase II
| NCT ID | NCT07331558 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Riphah International University |
| Condition | CABG |
| Study Type | INTERVENTIONAL |
| Enrollment | 66 participants |
| Start Date | 2025-12-02 |
| Primary Completion | 2026-02-25 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 66 participants in total. It began in 2025-12-02 with a primary completion date of 2026-02-25.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
It will be a randomized clinical trial with a sample size of 66. A convenient sampling technique will be used to recruit the CABG phase II patients for the study. Then, they will be divided into three groups by block randomization. Weight-bearing Liuzijue Qigong will be given as a baseline treatment to all groups. In group A, patients will engage in multimodal circuit training while simultaneously viewing the nature scenes through VR in a clinical setting, in group B, patients will be given multimodal circuit training in a clinical setting while in group C, patients will be given multimodal circuit training through telerehabilitation. The dyspnea 12 Questionnaire will be used for measuring dyspnea, Cooper's 12-minute test will be used to assess cardiorespiratory fitness, echocardiography will be used to assess Left ventricular ejection fraction, EQ-5D-5L will be used to assess quality of life, and Pittsburgh Sleep Quality Index (PSQI) will be used to assess the quality of sleep. Data will be entered and analyzed through SPSS version 21.
Eligibility Criteria
Inclusion Criteria: * Patients who underwent CABG surgery will be recruited after twelve weeks * Both male and female * Age 30-60 years old * LVEF of \< 40% * Persistent dyspnea with a self-rated intensity of ⩾5 (out of 10) on a visual analogue dyspnea scale (this dyspnea rating was only used as an inclusion criterion and not as a measure for outcome) * Preserved cognitive function (Montreal Cognitive Assessment score \>24) Exclusion Criteria: * Patient with recurrent history of CABG * Had a non-cardiac surgical procedure ≤2 months prior to recruitment * Unstable angina, uncontrolled hypertension (blood pressure \>180/100 mmHg), a pacemaker or atrial fibrillation, documented peak orifice area valve stenosis, symptomatic peripheral arterial disease that limits exercise capacity. * Documented chronic obstructive pulmonary disease (FEV1 \<60% and FVC \<60%) * Any shoulder impairment that would limit exercise participation * Patients with Kinesiophobia * Epilepsy, vertigo, eyesight impairment (conditions contraindicated for VR)
Contact & Investigator
Wajeeha Zia, PP-DPT
PRINCIPAL INVESTIGATOR
Riphah International University
Frequently Asked Questions
Who can join the NCT07331558 clinical trial?
This trial is open to participants of all sexes, aged 30 Years or older, up to 60 Years, studying CABG. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07331558 currently recruiting?
Yes, NCT07331558 is actively recruiting participants. Contact the research team at wajeeha.zia@riphah.edu.pk for enrollment information.
Where is the NCT07331558 trial being conducted?
This trial is being conducted at Lahore, Pakistan.
Who is sponsoring the NCT07331558 clinical trial?
NCT07331558 is sponsored by Riphah International University. The principal investigator is Wajeeha Zia, PP-DPT at Riphah International University. The trial plans to enroll 66 participants.